- Product Details
Keywords
- imatinib
- 152459-95-5
- C29H31N7O
Quick Details
- ProName: imatinib
- CasNo: 152459-95-5
- Molecular Formula: C29H31N7O
- Appearance: Off-white to brown powder
- Application: Tyrosine kinase inhibitor. It is used ...
- DeliveryTime: 2 weeks after confirming the order
- PackAge: 25kg/bag/drum,according to customer's ...
- Port: QINGDAO/SHANGHAI/SHENZHEN/HONGKONG
- ProductionCapacity: 100 Kilogram/Week
- Purity: ≥98.5%
- Storage: Storage in warehouse with well-ventila...
- Transportation: By air/by sea/ by express
- LimitNum: 100 Gram
Superiority
Henan Wising Chem Co., Ltd is a national high-tech enterprise with a passion for selling and an emphasis on customer care.
We are committed to providing quality chemical products that help us become one of the most reputable, reliable and leading chemical products suppliers in the domestic and global markets.
We purpose to bring our value clients the best quality products, the most competitive prices, the shortest delivery and the best service.
Our customers include BASF, Bayer, Merck, AstraZeneca, Sun Pharma, Shanghai Pharmaceuticals, MSN Laboratories, Unither Pharmaceuticals, Cadila Healthcare, and Abbott, Amgen in the US.
Wising Chem is a reliable distributor in domestic and global markets, we own an excellent reserch team based on Zhengzhou University, Shanghai Medical College of Fudan University and Henan University of Animal Husbandry&Economy, we focus on Pharmaceutical intermediates, API, rare chemiclas, and fine chemicals.
Details
Tyrosine kinase inhibitor. It is used for chronic myeloid leukemia (CML) in the progenitor cell critical phase, accelerated phase, and chronic phase when alpha interferon therapy is ineffective, as well as gastrointestinal interstitial tumors (GIST). Imatinib mesylate inhibited Bcr-Abl tyrosine kinase at the cellular level both in vitro and in vivo, and selectively inhibited proliferation and induced apoptosis in fresh cells of Bcr-Abl-positive cell lines, Ph chromosome-positive chronic granulocytic leukemia and acute lymphoblastic leukemia patients. In addition, imatinib mesylate inhibited platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), and c-Kit receptor tyrosine kinase, thereby inhibiting cellular behavior mediated by PDGF and stem cell factor.